Together, these findings lead to a model whereby GDI2 exerts a regulatory and suppressive effect in HER2+ breast cancer cells, limiting activation of RAB5 and constraining αVβ6-dependent HER2 trafficking, signaling, and invasion (Fig. 7A). Here, ERBB2 is linked to breast carcinoma.